Zobrazeno 1 - 10
of 16
pro vyhledávání: ''
Autor:
Danielle S. Bitterman, Miranda B. Lam, Nayan Lamba, Sana Raoof, Daniel Kim, Amandeep R. Mahal, Grace M. Lee, Nina N. Sanford, Harvey J. Mamon
Publikováno v:
Molecular and Clinical Oncology
There are few treatment guidelines for locally recurrent esophageal cancer after trimodality treatment (pre-operative chemoradiation followed by surgery) in patients with a poor performance status. The purpose of this single institutional, retrospect
Autor:
Yusuke Nakamura, Noriyuki Yamada, Ryo Takata, Toyomasa Katagiri, Tomohiko Matsuura, Hitoshi Zembutsu, Mitsugu Kanehira, Wataru Obara, Yoichiro Kato, Tamotsu Sugai, Renpei Kato, Tomoaki Fujioka, Kazuhiro Iwasaki
Publikováno v:
Oncology Letters
The present study established systems to predict the chemo-sensitivity of muscle invasive bladder cancer (MIBC) for neoadjuvant chemotherapy (NAC) with methotrexate, vinblastine, doxorubicin plus cisplatin (M-VAC) and carboplatin plus gemcitabine (Ca
The present study aimed to investigate the significance of the neutrophil to lymphocyte ratio (NLR) in peripheral blood of patients with small cell lung cancer (SCLC) when selecting a first-line treatment. A total of 73 patients with SCLC who had com
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29a17a24deaa969f372c574341ee67ae
https://europepmc.org/articles/PMC6607396/
https://europepmc.org/articles/PMC6607396/
Autor:
Yoshiro Nakahara, Shinya Harada, Masayuki Shirasawa, Noriyuki Masuda, Jiichiro Sasaki, Hideyuki Niwa, Yasuhiro Hiyoshi, Takahiro Ozawa, Seiichiro Kusuhara, Masashi Kasajima
Publikováno v:
Molecular and Clinical Oncology
Pegfilgrastim is a long-acting granulocyte colony-stimulating factor formulation that has been approved for the prevention of febrile neutropenia. We herein report a case of interstitial pneumonia following administration of pegfilgrastim. A 65-year-
The present study describes the case of a 48-year-old man who was diagnosed with lung adenocarcinoma with an epidermal growth factor receptor (EGFR) 21 L858R mutation. The patient received surgery and adjuvant chemotherapy. When multiple lung metasta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6fa03e4a787fcc79460dd0b2eaa8731
https://europepmc.org/articles/PMC5840615/
https://europepmc.org/articles/PMC5840615/
Efficacy of TCH/TEC neoadjuvant chemotherapy for the treatment of HER-2-overexpressing breast cancer
Publikováno v:
Oncology Letters
The aim of the present study was to observe the efficacy of neoadjuvant trastuzumab combined with docetaxel and carboplatin (TCH), and docetaxel, epirubicin and cyclophosphamide (TEC) chemotherapy in human epidermal growth factor receptor-2 (HER-2)-o
Autor:
Mina Hayashi, Hiroyuki Sugimoto, Takayasu Kurata, Noriko Inagaki, Shosaku Nomura, Tsutomu Tanijiri, Takayuki Miyara, Yuichi Katashiba, Toshiki Shimizu, Maiko Niki, Kayoko Kibata, Takashi Yokoi, Makoto Ogata, Yoshitaro Torii
Publikováno v:
Oncology Letters
The present study evaluated the efficacy and safety of pemetrexed, carboplatin and bevacizumab, followed by maintenance pemetrexed and bevacizumab, in chemotherapy-naive patients with stage IIIB/IV non-squamous non-small cell lung cancer (NSCLC). The
Autor:
Morikazu Miyamoto, Masashi Takano, Ayako Suzuki, Takashi Shibutani, Tomoyuki Yoshikawa, Junko Hirata, Hiroaki Soyama, Tadashi Aoyama, Hidenori Sasa, Kenichi Furuya
Non-platinum single agents are usually used for patients with platinum-resistant recurrent ovarian cancers (ROC). However, the efficacy of these drugs is limited. The aim of the present study was to evaluate the efficacy and adverse events (AE) of co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::efd231256504e3b1f1c1bff48fa462ed
https://europepmc.org/articles/PMC5492769/
https://europepmc.org/articles/PMC5492769/
Autor:
Yoshihiro Takai, Katsumi Hirose, Yoshiomi Hatayama, Masahiko Aoki, Mariko Sato, Yuichiro Narita, Hideo Kawaguchi
Publikováno v:
Molecular and Clinical Oncology
The nasal type of extranodal natural killer (NK)/T-cell lymphoma (NKTCL) is a rare aggressive lymphoma with poor prognosis. The reported 5-year overall survival for patients with localized nasal NKTCL treated with cyclophosphamide, hydroxydaunorubici
Publikováno v:
Oncology Letters
No standard therapy for pulmonary epithelioid hemangioendothelioma (PEH) has yet been established due to the rarity of the disease, the lack of clear standards for treatment and the partial-to-complete spontaneous regression. This report describes th